Czamira Nordstrom, APRN
Primary Care · Honolulu, HINPI 1407209265
Payments from drug & device makers
What this record shows
Inspire Medical Systems, Inc. accounts for 80.9% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $4,140, more than ten times the $272 reported in 2021. Among primary care clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $81.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$8K
- Sanofi$775
- GSK$447
- Insmed, Inc.$350
- Pharming Healthcare, Inc.$170
- Medtronic$67
- plus $179 from 6 others
What the payments were for
- Travel & lodging$5,65855%
- Food & beverage$4,72145%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 41 | $8,393 |
| Sanofi | 12 | $775 |
| GSK | 58 | $447 |
| Insmed, Inc. | 5 | $350 |
| Pharming Healthcare, Inc. | 3 | $170 |
| Medtronic | 1 | $67 |
| Genentech USA, Inc. | 3 | $57 |
| Advanced Respiratory, Inc | 1 | $43 |
| AstraZeneca | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| AbbVie | 1 | $16 |
| Resmed Corp | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$7,307
- DUPIXENT$456
- Inspire Upper Airway Stimulation System$281
- Arikayce$244
- JOENJA$118
How this compares
$10,380 in reported general payments places this provider in the 95th percentile of 24 primary care providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 85 | $317,036 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 246 | $225,967 |
| Fasenra PenBenralizumab | 34 | $186,799 |
| Dupixent PenDupilumab | 37 | $141,864 |
| TezspireTezepelumab-Ekko | 20 | $87,713 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 66 | $52,032 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $48,147 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $27,093 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $22,885 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $17,417 |
| Spiriva RespimatTiotropium Bromide | 16 | $12,511 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $9,253 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 14 | $8,327 |
| Arnuity ElliptaFluticasone Furoate | 17 | $7,762 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $7,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $447 | $609,995431 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Bevespi Aerosphere, Symbicort | $26 | $151,329108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 24 primary care providers in Hawaii.
Other primary care in Honolulu
- Hye Won KangHonolulu$9K
- John AbesamisHonolulu$6K
- Rebecca Fojas-CalimpongHonolulu$6K
- Donita ValdezHonolulu$2K
- Anthone JeonHonolulu$693
- Gayane BejanyanHonolulu$55
- Brittney WhalenKaneohe$5K
- Rizelle TalonWaipahu$5K
- Johanna AuKapolei$5K
- Michelle OjiriHilo$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.